noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

AstraZeneca Pharmaceuticals LP

Results AstraZeneca Pharmaceuticals LP

AstraZeneca Pharmaceuticals LP

AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D

-2d
AstraZeneca Pharmaceuticals LP

TAGRISSO® (osimertinib) plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer

-3d
AstraZeneca Pharmaceuticals LP

Update on CARES Phase III clinical program of anselamimab in light chain amyloidosis

7/17
AstraZeneca Pharmaceuticals LP

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

7/14
AstraZeneca Pharmaceuticals LP

Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

6/24
AstraZeneca Pharmaceuticals LP

AstraZeneca’s Mount Vernon, Indiana Supply Site Earns its first EPA’s ENERGY STAR® Certification for Superior Energy Efficiency

6/6
AstraZeneca Pharmaceuticals LP

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial

6/2
AstraZeneca Pharmaceuticals LP

Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

6/1
AstraZeneca Pharmaceuticals LP

IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

6/1
AstraZeneca Pharmaceuticals LP

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer

5/21